With a unique background spanning big pharma, private practice, and scientific research, Rose Hughes is ideally positioned to secure robust IP protection for your innovative cell and gene therapy technologies. Rose is passionate about developing IP strategies that secure investment, accelerate clinical success, and ultimately bring these groundbreaking treatments to patients.

As the former IP Lead for Biopharma Cell Therapy at AstraZeneca, Rose drove the IP strategy for high-priority programs, including CAR-T, allogeneic therapies, in vivo strategies, and regenerative medicine. Rose has extensive expertise in due diligence and deal negotiation for high-value transactions involving both platform technologies and clinical-stage cell and gene therapy products.

Rose combines a PhD in Immunology from UCL with over a decade of patent experience. Now a patent attorney at the pharma IP specialist firm Evolve Intellectual Property, Rose develops innovative IP strategies that align with your commercial goals and deliver tangible business value.